Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

ASCO 2020

Videos
News
PARP inhibitors and prostate cancer: A new era of precision medicine
Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain
PARP inhibitors and prostate cancer: A new era of precision medicine ( Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
4 Aug 2020
Oncology pharmacist perspective on PARP inhibitors for castration-resistant...
Dr Grace Martin - The University of Kansas Cancer Center, Kansas City, USA
Oncology pharmacist perspective on PARP inhibitors for castration-resistant prostate cancer ( Dr Grace Martin - The University of Kansas Cancer Center, Kansas City, USA )
27 Jul 2020
The role of PARP-2 in inhibiting prostate cancer
Prof Li Jia - Harvard Medical School, Boston, USA
The role of PARP-2 in inhibiting prostate cancer ( Prof Li Jia - Harvard Medical School, Boston, USA )
27 Jul 2020
Lung cancer updates from ASCO 2020
Dr Luis Raez - Memorial Cancer Institute, Florida, USA
Lung cancer updates from ASCO 2020 ( Dr Luis Raez - Memorial Cancer Institute, Florida, USA )
17 Jul 2020
KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with...
Prof Scott Tykodi - University of Washington, Seattle, USA
KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear cell renal cell carcinoma ( Prof Scott Tykodi - University of Washington, Seattle, USA )
14 Jul 2020
Association of gene expression with clinical outcomes in RCC patients treated...
Prof Scott Tykodi - University of Washington, Seattle, USA
Association of gene expression with clinical outcomes in RCC patients treated with pembrolizumab ( Prof Scott Tykodi - University of Washington, Seattle, USA )
14 Jul 2020
Renal cell cancer: Highlights from ASCO 2020
Prof Scott Tykodi - University of Washington, Seattle, USA
Renal cell cancer: Highlights from ASCO 2020 ( Prof Scott Tykodi - University of Washington, Seattle, USA )
13 Jul 2020
FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment...
Prof Scott Tykodi - University of Washington, Seattle, USA
FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory advanced renal cell carcinoma ( Prof Scott Tykodi - University of Washington, Seattle, USA )
13 Jul 2020
HERO: Relugolix versus leuprolide acetate for advanced prostate cancer
Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA
HERO: Relugolix versus leuprolide acetate for advanced prostate cancer ( Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA )
10 Jul 2020
The future of PARP inhibitors in prostate cancer
Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain
The future of PARP inhibitors in prostate cancer ( Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain )
2 Jul 2020
COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected...
Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600–mutant melanoma ( Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
30 Jun 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC ( Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
30 Jun 2020
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer
Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )
24 Jun 2020
MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant...
Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal
MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in breast cancer ( Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal )
18 Jun 2020
CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )
17 Jun 2020
Early safety from a trial of talimogene laherparepvec (T-VEC) injected into...
Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica...
Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab ( Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, USA )
17 Jun 2020
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma ( Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA )
16 Jun 2020
Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin...
Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada
Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma ( Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada )
16 Jun 2020
FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO...
Prof Robert Huddart and Dr Ignacio Durán
FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020 ( Prof Robert Huddart and Dr Ignacio Durán )
15 Jun 2020
Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for...
Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA
Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma ( Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA )
15 Jun 2020
High-dose twice daily thoracic radiotherapy in limited disease small-cell lung...
Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway
High-dose twice daily thoracic radiotherapy in limited disease small-cell lung cancer ( Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway )
15 Jun 2020
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
15 Jun 2020
Background of the KEYLYNK-007 trial for advanced solid tumours
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
Background of the KEYLYNK-007 trial for advanced solid tumours ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Jun 2020
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation...
Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer ( Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )
12 Jun 2020
CTC count as a prognostic marker for androgen deprivation plus orteronel or...
Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA
CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC ( Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA )
12 Jun 2020
AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in...
Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany
AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer ( Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany )
12 Jun 2020
Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based...
Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy
Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer ( Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy )
12 Jun 2020
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma
Dr Katie Kelley - University of California San Francisco, San Francisco, USA
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma ( Dr Katie Kelley - University of California San Francisco, San Francisco, USA )
12 Jun 2020
Reducing damage to swallowing muscles during radiotherapy for head and neck...
Prof Christopher Nutting - The Royal Marsden NHS Foundation Trust, London, UK
Reducing damage to swallowing muscles during radiotherapy for head and neck cancers ( Prof Christopher Nutting - The Royal Marsden NHS Foundation Trust, London, UK )
12 Jun 2020
Comment: JAVELIN-100 for metastatic urothelial cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
Comment: JAVELIN-100 for metastatic urothelial cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )
12 Jun 2020
HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve...
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )
12 Jun 2020
Updated results from KEYNOTE-426 for metastatic kidney cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
Updated results from KEYNOTE-426 for metastatic kidney cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )
12 Jun 2020
3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and...
Dr Naomi Kiyota - Kobe University, Kobe, Japan
3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and neck ( Dr Naomi Kiyota - Kobe University, Kobe, Japan )
12 Jun 2020
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung...
Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer ( Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA )
12 Jun 2020
METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer
Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA
METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer ( Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA )
12 Jun 2020
PARP inhibitors in prostate cancer: Choices of tests and how to test?
Dr Kim Chi and Dr Alexander Wyatt
PARP inhibitors in prostate cancer: Choices of tests and how to test? ( Dr Kim Chi and Dr Alexander Wyatt )
11 Jun 2020
ASCO 2020: Breast cancer roundup
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ASCO 2020: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
11 Jun 2020
FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple...
Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy
FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )
11 Jun 2020
The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients...
Dr Sara Lonardi - Istituto Oncologico Veneto, Padua, Italy
The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT metastatic colorectal cancer ( Dr Sara Lonardi - Istituto Oncologico Veneto, Padua, Italy )
11 Jun 2020
Comparing pevonedistat plus azacitidine versus azacitidine alone in patients...
Prof Lionel Ades - Hôpital Saint-Louis, Paris, France
Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML ( Prof Lionel Ades - Hôpital Saint-Louis, Paris, France )
11 Jun 2020
ASCO 2020 prostate cancer highlights
Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl
ASCO 2020 prostate cancer highlights ( Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl )
10 Jun 2020
Perioperative novel systemic immunotherapy-based approaches in urinary cancers
Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA
Perioperative novel systemic immunotherapy-based approaches in urinary cancers ( Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA )
9 Jun 2020
ASCO 2020: Updates in renal cancer
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ASCO 2020: Updates in renal cancer ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
5 Jun 2020
TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to...
Prof Benoit You - Hospices Civils de Lyon, Lyon, France
TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy ( Prof Benoit You - Hospices Civils de Lyon, Lyon, France )
5 Jun 2020
KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H...
Prof Thierry Andre - Sorbonne University and Saint-Antoine Hospital, Paris...
KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal cancer ( Prof Thierry Andre - Sorbonne University and Saint-Antoine Hospital, Paris, France )
5 Jun 2020
Highlights from ASCO 2020
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ASCO 2020 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
5 Jun 2020
PARP inhibitors in prostate cancer: Guidelines, who to test and the patient...
Dr Neal Shore and Dr Elena Castro
PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway ( Dr Neal Shore and Dr Elena Castro )
5 Jun 2020
New emerging treatment options and targeted therapies for bladder cancer
Dr Arlene Siefker-Radtke and Dr Yohann Loriot
New emerging treatment options and targeted therapies for bladder cancer ( Dr Arlene Siefker-Radtke and Dr Yohann Loriot )
4 Jun 2020
Timing of response to venetoclax combination treatment in older patients with...
Dr Brian Jonas - University of California Davis Comprehensive Cancer Center...
Timing of response to venetoclax combination treatment in older patients with acute myeloid leukaemia ( Dr Brian Jonas - University of California Davis Comprehensive Cancer Center, Sacramento, USA )
3 Jun 2020
CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as...
Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta...
CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first-line treatment for advanced NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )
2 Jun 2020
ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer
Prof Benjamin Besse and Dr Alex Spira
ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer ( Prof Benjamin Besse and Dr Alex Spira )
2 Jun 2020
Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple...
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
1 Jun 2020
KRd vs VRd for initial therapy of newly diagnosed multiple myeloma
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
KRd vs VRd for initial therapy of newly diagnosed multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
1 Jun 2020
Teclistamab for patients with heavily pretreated relapsed or refractory...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )
1 Jun 2020
E2108: Systemic therapy plus early local therapy versus systemic therapy alone...
Dr Seema Ahsan Khan - Northwestern Memorial Hospital, Chicago, USA
E2108: Systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer ( Dr Seema Ahsan Khan - Northwestern Memorial Hospital, Chicago, USA )
31 May 2020
KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy...
Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA
KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-stage small-cell lung cancer ( Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA )
31 May 2020
Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and...
Dr Dimpy Shah - Mays Cancer Center at UT Health San Antonio MD Anderson, San...
Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19) ( Dr Dimpy Shah - Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, USA )
31 May 2020
Cumulative incidence of financial hardship in metastatic colorectal cancer...
Dr Veena Shankaran - Fred Hutchinson Cancer Research Center, Seattle, USA
Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD ( Dr Veena Shankaran - Fred Hutchinson Cancer Research Center, Seattle, USA )
30 May 2020
Denosumab in multiple myeloma patients with renal insufficiency
Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA
Denosumab in multiple myeloma patients with renal insufficiency ( Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA )
30 May 2020
Association of BRCA alterations with response to PARP inhibitors in metastatic...
Dr Emmanuel Antonarakis - John Hopkins Sidney Kimmel Comprehensive Cancer...
Association of BRCA alterations with response to PARP inhibitors in metastatic castration-resistant prostate cancer ( Dr Emmanuel Antonarakis - John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
30 May 2020
LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer...
Prof Michael Hofman - Peter MacCallum Cancer Centre, Melbourne, Australia
LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docetaxel ( Prof Michael Hofman - Peter MacCallum Cancer Centre, Melbourne, Australia )
30 May 2020
The paediatric precision oncology study INFORM: Clinical outcome and benefit...
Dr Cornelis van Tilburg - Hopp Children's Cancer Center Heidelberg, Heidelberg...
The paediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups ( Dr Cornelis van Tilburg - Hopp Children's Cancer Center Heidelberg, Heidelberg, Germany )
30 May 2020
Maintenance avelumab plus best supportive care (BSC) versus BSC alone after...
Prof Thomas Powles - Barts Cancer Institute, London, UK
Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chemotherapy in advanced urothelial carcinoma ( Prof Thomas Powles - Barts Cancer Institute, London, UK )
29 May 2020
Better genetic diagnostics in Ugandan breast cancer patients
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
Better genetic diagnostics in Ugandan breast cancer patients ( Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA )
29 May 2020
Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA...
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer ( Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA )
29 May 2020
Update from KAITLIN for high-risk HER2-positive early breast cancer
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
Update from KAITLIN for high-risk HER2-positive early breast cancer ( Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA )
29 May 2020
CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell...
Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA
CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy for r/r multiple myeloma ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )
29 May 2020
Sym015 shows superior specificity compared to TKIs for NSCLC
Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA
Sym015 shows superior specificity compared to TKIs for NSCLC ( Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA )
29 May 2020
Brigatinib for NSCLC, latest research and overcoming complications
Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA
Brigatinib for NSCLC, latest research and overcoming complications ( Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA )
29 May 2020
ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer
Prof Roy Herbst - Yale Cancer Center, New Haven, USA
ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )
29 May 2020
Pembrolizumab plus chemotherapy for patients with metastatic triple-negative...
Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain
Pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast cancer ( Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain )
27 May 2020

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation